Physician profile
Sophia E Ro
NPI 1336537547
$1,115.72
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $670 · 2022: $445.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $461.46 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $299.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $170.97 | 2021-2022 | |
| Genzyme Corporation | $93.23 | 2021-2022 | |
| Neurent Medical Limited | $66.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sophia Ro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.